About iQure Pharma
iQure Pharma is a private company based in Skillman, New Jersey. It has reported $6,602,101 raised in five offerings on Form D since October 2023. Its chief executive is Pawel Zolnierczyk.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 27, 2026 | Jun 3, 2026 | $650,000of $4.0M target | 1 | $650K | EquityRule 506(b) | Form D ↗ |
| Sep 9, 2025 | Nov 3, 2025amended Sep 21, 2026 | $2,788,315of $4.0M target | 18 | $154K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 20, 2024 | Jan 16, 2025 | $1,443,786fully sold | 2 | $721K | DebtRule 506(b) | Form D ↗ |
| Apr 5, 2024 | Apr 16, 2024 | $220,000target not set | 7 | $31,429 | DebtRule 506(b) | Form D ↗ |
| Oct 4, 2023 | Oct 11, 2023 | $1,500,000of $2.0M target | 13 | $115K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $6,602,101 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on iQure Pharma's Form D filed Jun 3, 2026.
